More recently, the anti-tumor efficacy of this DS-8201a was confirmed on a prospective, two-phase, dose-finding, phase 2 trial for patients with HER2+, heavily pre-treated, progressive MBC (DESTINY-01), leading to accelerated FDA approval of this novel agent on 23 December 201944. Here, ERBB2 is linked to neoplasm.